Anna Skiada

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9303260/publications.pdf

Version: 2024-02-01

20 papers

4,210 citations

430874 18 h-index 752698 20 g-index

55 all docs

55 docs citations

55 times ranked 4211 citing authors

#	Article	IF	CITATIONS
1	Epidemiology and Clinical Manifestations of Mucormycosis. Clinical Infectious Diseases, 2012, 54, S23-S34.	5.8	1,061
2	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infectious Diseases, The, 2019, 19, e405-e421.	9.1	970
3	ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica, 2017, 102, 433-444.	3 . 5	468
4	Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infectious Diseases, The, 2018, 18, 391-400.	9.1	400
5	Epidemiology and Diagnosis of Mucormycosis: An Update. Journal of Fungi (Basel, Switzerland), 2020, 6, 265.	3.5	381
6	Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica, 2013, 98, 492-504.	3. 5	282
7	Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries. BMC Infectious Diseases, 2016, 16, 667.	2.9	109
8	Global epidemiology of cutaneous zygomycosis. Clinics in Dermatology, 2012, 30, 628-632.	1.6	89
9	Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial. Clinical Infectious Diseases, 2019, 69, 769-776.	5.8	83
10	Adaptive resistance to cationic compounds in Pseudomonas aeruginosa. International Journal of Antimicrobial Agents, 2011, 37, 187-193.	2.5	64
11	Carbapenemase-producing Klebsiella pneumoniae bloodstream infections in neutropenic patients with haematological malignancies or aplastic anaemia: Analysis of 50 cases. International Journal of Antimicrobial Agents, 2016, 47, 335-339.	2.5	61
12	Colistin plus meropenem for carbapenem-resistant Gram-negative infections: inÂvitro synergism is not associated with better clinical outcomes. Clinical Microbiology and Infection, 2020, 26, 1185-1191.	6.0	46
13	Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol. BMJ Open, 2016, 6, e009956.	1.9	41
14	Connecting the Dots: Interplay of Pathogenic Mechanisms between COVID-19 Disease and Mucormycosis. Journal of Fungi (Basel, Switzerland), 2021, 7, 616.	3.5	40
15	The Association Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: A Prospective Study. Clinical Infectious Diseases, 2018, 67, 1815-1823.	5.8	29
16	Global Cutaneous Mucormycosis: A Systematic Review. Journal of Fungi (Basel, Switzerland), 2022, 8, 194.	3.5	28
17	Cutaneous mucormycosis. Skinmed, 2013, 11, 155-9; quiz 159-60.	0.0	25
18	Rare fungal infectious agents: a lurking enemy. F1000Research, 2017, 6, 1917.	1.6	24

#	Article	IF	CITATIONS
19	Large-scale WGS of carbapenem-resistant <i>Acinetobacter baumannii</i> isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance. Journal of Antimicrobial Chemotherapy, 2022, 77, 934-943.	3.0	5
20	Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity. BMC Infectious Diseases, 2021, 21, 309.	2.9	4